Evidence map›Paper›PMID 31022997›Full record

ReviewInternational journal of stem cells2019

Efficacies of Stem Cell Therapies for Functional Improvement of the

Gyudeok Hwang, Hyunsuk Jeong, Hae Kyung Yang, Hun-Sung Kim, Hanter Hong, Na Jin Kim, Il-Hoan Oh, Hyeon Woo Yim

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of stem cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment.Endocrine, metabolic & immune disorders drug targets · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Gyudeok HwangThe Catholic University of Korea, Catholic Medical Center, Seoul, Korea.
Hyunsuk JeongDepartment of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hae Kyung YangCell and Gene Therapy Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, Korea.
Hun-Sung KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hanter HongThe Catholic University of Korea, Catholic Medical Center, Seoul, Korea.
Na Jin KimMedical Library, The Catholic University of Korea, Seoul, Korea.
Il-Hoan OhCatholic High-Performance Cell Therapy Center & Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyeon Woo YimDepartment of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Catholic University of Korea · KRMinistry of Food and Drug Safety · KRSeoul St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThis study was performed to investigate whether stem cell therapy enhances

methodsA systematic search was performed from inception to January 2018 in PubMed, EMBASE, and Cochrane databases.

resultsFrom the selected final 15 articles, total of 16 trials were analyzed. There were 6 T1DM trials (total 153 cases) and 10 T2DM trials (total 457 cases). In T2DM patients, the changes in stimulated C-peptide, HbA1c, and exogenous insulin dose versus baseline showed a favorable pattern with a significant heterogeneity in stem cell therapy. In T1DM, there was no significant difference between control group and stem cell therapy group in three indicators except for HbA1c. Most of the studies were rated as having high risk of bias in the quality assessment.

conclusionsThe stem cell therapy for DM patients is not effective in T1DM but seems to be effective in improving the

Indexed as

C-peptideDiabetes mellitusStem cellβ cell

Identifiers

PMID31022997
PMCPMC6657948
OpenAlexW2942452272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.